Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The development of a vaccine against visceral leishmaniasis (VL) conferring long-lasting immunity remains a challenge. Identification and proteomic characterization of parasite proteins led to the detection of p45, a member of the methionine aminopeptidase family. To our knowledge the present study is the first known report that describes the molecular and immunological characterization of p45. Recombinant Leishmania donovani p45 (rLdp45) induced cellular responses in cured hamsters and generated Th1-type cytokines from peripheral blood mononuclear cells of cured/endemic VL patients. Immunization with rLdp45 exerted considerable prophylactic efficacy (∼85%) supported by an increase in mRNA expression of iNOS, IFN-γ, TNF-α and IL-12 and decrease in TGF-β and IL-4, indicating its potential as a vaccine candidate against VL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijpara.2012.02.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis.
Med Microbiol Immunol
September 2025
Instituto de Patología Experimental, Universidad Nacional de Salta/Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Salta, Argentina.
Advances in recombinant protein vaccines against Leishmania infantum: a systematic review of vaccinal constructs and delivery strategies.
Acta Trop
August 2025
Laboratory of Immunobiology and Control of Parasites, Postgraduate Program in Parasitology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Postgraduate Program in Health Sciences, School of Medicine, Federal University of Minas Gerais, Bel
Leishmaniasis remains one of the most prevalent neglected tropical diseases, with Leishmania infantum being a major cause of visceral leishmaniasis, a potentially fatal condition if left untreated. Despite advances in vaccine development, no human vaccine is currently licensed, highlighting the urgent need for innovative immunization strategies. Recombinant protein-based vaccines have emerged as promising candidates due to their capacity to induce targeted immune responses.
View Article and Find Full Text PDFEvaluation of homolog of activated C kinase (LACK) of in comparison to glycoprotein 63 as a vaccine candidate against visceral leishmaniasis.
Microbiol Spectr
August 2025
Infectious Diseases and Immunology Divison, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Biology, Kolkata, India.
Leishmaniasis, caused by protozoa transmitted via sand fly bites, affects over 12 million people annually, manifesting as self-limiting cutaneous lesions or fatal visceral leishmaniasis (VL). The disease's immune response involves a Th1/Th2 paradigm, with Th1 promoting resistance and Th2 linked to susceptibility. Despite no available human vaccine, the homolog of activated C kinase (LACK) protein has shown promise as a candidate due to its conservation across species.
View Article and Find Full Text PDFThe F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against () mice infection.
Front Immunol
July 2025
Laboratório de Biologia e Bioquímica de Leishmania, Instituto de Microbiologia Paulo de Góes, Departamento de Microbiologia Geral, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Introduction: Visceral leishmaniasis (VL) is a severe human vector-borne CD4-immunosuppressive disease that can be lethal if untreated soon after symptoms arise. No vaccine is available against human VL, and its chemotherapy is highly toxic and requires hospitalization. VL patients show substantially decreased CD4 total and -specific CD4+ T cell counts.
View Article and Find Full Text PDFRecombinant Leishmania-activated C kinase as a novel antigenic candidate for immuno-diagnosis of visceral leishmaniasis occurring in India and Brazil.
Infect Dis Poverty
July 2025
(CSIR)-Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata, West Bengal, India.
Background: Visceral leishmaniasis (VL) an 'infectious disease of poverty', caused by the Leishmania donovani complex, remains a significant public health threat in endemic regions of South Asia, East Africa, and Brazil. Early and accurate diagnosis is critical to prevent the disease's potentially fatal outcomes. However, due to the nonspecific nature of clinical symptoms, diagnosis often relies on serological tests.
View Article and Find Full Text PDF